LRCX vs. LLY

Last updated Apr 1, 2026

Compare and contrast key facts about Lam Research Corporation (LRCX) and Eli Lilly and Company (LLY).

Performance

LRCX vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lam Research Corporation (LRCX) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

LRCX vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LRCX Lam Research Corporation	24.97%	139.16%	-6.84%	88.63%	-40.72%	53.66%	64.18%	119.33%	-24.40%	76.21%
LLY Eli Lilly and Company	-14.27%	40.25%	33.30%	60.91%	34.26%	66.08%	31.04%	16.14%	40.45%	17.83%

Fundamentals

Market Cap LRCX : $270.39B LLY : $825.96B
EPS LRCX : $4.89 LLY : $22.96
PE Ratio LRCX : 43.69 LLY : 40.06
PEG Ratio LRCX : 3.31 LLY : 0.81
PS Ratio LRCX : 13.20 LLY : 12.68
PB Ratio LRCX : 26.65 LLY : 31.13
Total Revenue (TTM) LRCX : $20.56B LLY : $65.18B
Gross Profit (TTM) LRCX : $10.24B LLY : $54.62B
EBITDA (TTM) LRCX : $7.43B LLY : $27.94B

Returns By Period

In the year-to-date period, LRCX achieves a 24.97% return, which is significantly higher than LLY's -14.27% return. Over the past 10 years, LRCX has outperformed LLY with an annualized return of 40.32%, while LLY has yielded a comparatively lower 30.92% annualized return.

LRCX

• 1D: 6.87%
• 1M: -8.54%
• YTD: 24.97%
• 6M: 60.02%
• 1Y: 196.05%
• 3Y*: 60.68%
• 5Y*: 28.66%
• 10Y*: 40.32%

LLY

• 1D: 3.74%
• 1M: -12.57%
• YTD: -14.27%
• 6M: 20.93%
• 1Y: 12.19%
• 3Y*: 39.90%
• 5Y*: 39.16%
• 10Y*: 30.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LRCX vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LRCX

LRCX Risk / Return Rank: 97
LRCX Sharpe Ratio Rank: 98
LRCX Sortino Ratio Rank: 95
LRCX Omega Ratio Rank: 95
LRCX Calmar Ratio Rank: 98
LRCX Martin Ratio Rank: 99

LLY

LLY Risk / Return Rank: 51
LLY Sharpe Ratio Rank: 53
LLY Sortino Ratio Rank: 48
LLY Omega Ratio Rank: 49
LLY Calmar Ratio Rank: 53
LLY Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LRCX vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lam Research Corporation (LRCX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LRCX	LLY	Difference
Sharpe ratio Return per unit of total volatility	3.67	0.29	+3.38
Sortino ratio Return per unit of downside risk	3.58	0.69	+2.90
Omega ratio Gain probability vs. loss probability	1.50	1.10	+0.40
Calmar ratio Return relative to maximum drawdown	9.82	0.42	+9.40
Martin ratio Return relative to average drawdown	31.04	1.02	+30.02
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LRCX vs. LLY - Sharpe Ratio Comparison

The current LRCX Sharpe Ratio is 3.67, which is higher than the LLY Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of LRCX and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LRCX	LLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.67	0.29	+3.38
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.63	1.23	-0.59
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.92	1.04	-0.12
Sharpe Ratio (All Time) Calculated using the full available price history	0.41	0.56	-0.15

Correlation

The correlation between LRCX and LLY is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LRCX vs. LLY - Dividend Comparison

LRCX's dividend yield for the trailing twelve months is around 0.47%, less than LLY's 0.68% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
LRCX Lam Research Corporation	0.47%	0.57%	1.19%	0.95%	1.53%	0.78%	1.04%	1.54%	2.79%	1.01%	1.28%	1.36%
LLY Eli Lilly and Company	0.68%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Drawdowns

LRCX vs. LLY - Drawdown Comparison

The maximum LRCX drawdown since its inception was -87.90%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for LRCX and LLY.

Drawdown Indicators

	LRCX	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-87.90%	-68.24%	-19.66%
Max Drawdown (1Y) Largest decline over 1 year	-20.01%	-30.26%	+10.25%
Max Drawdown (5Y) Largest decline over 5 years	-56.39%	-34.48%	-21.91%
Max Drawdown (10Y) Largest decline over 10 years	-56.39%	-34.48%	-21.91%
Current Drawdown Current decline from peak	-14.26%	-17.00%	+2.74%
Average Drawdown Average peak-to-trough decline	-28.31%	-19.25%	-9.06%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.33%	12.39%	-6.06%

Volatility

LRCX vs. LLY - Volatility Comparison

Lam Research Corporation (LRCX) has a higher volatility of 20.58% compared to Eli Lilly and Company (LLY) at 9.04%. This indicates that LRCX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LRCX	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	20.58%	9.04%	+11.54%
Volatility (6M) Calculated over the trailing 6-month period	40.44%	26.21%	+14.23%
Volatility (1Y) Calculated over the trailing 1-year period	53.75%	42.44%	+11.31%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	45.53%	32.14%	+13.39%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	44.09%	29.80%	+14.29%

Financials

LRCX vs. LLY - Profitability Comparison

The chart below illustrates the profitability comparison between Lam Research Corporation and Eli Lilly and Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

LRCX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Lam Research Corporation reported a gross profit of 2.65B and revenue of 5.34B. Therefore, the gross margin over that period was 49.6%.

LLY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a gross profit of 16.41B and revenue of 19.29B. Therefore, the gross margin over that period was 85.1%.

LRCX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Lam Research Corporation reported an operating income of 1.81B and revenue of 5.34B, resulting in an operating margin of 33.9%.

LLY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported an operating income of 8.78B and revenue of 19.29B, resulting in an operating margin of 45.5%.

LRCX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Lam Research Corporation reported a net income of 1.59B and revenue of 5.34B, resulting in a net margin of 29.8%.

LLY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a net income of 6.64B and revenue of 19.29B, resulting in a net margin of 34.4%.